Limits...
Tanshinone IIA attenuates experimental autoimmune encephalomyelitis in rats.

Yan J, Yang X, Han D, Feng J - Mol Med Rep (2016)

Bottom Line: Tanshinone IIA (TSIIA), one of the major fat‑soluble components of Salvia miltiorrhiza (Danshen), has anti‑inflammatory, immunoregulatory and neuroprotective activity; however, its efficacy in MS remains unknown.Following administration of TSIIA, the quantity of CD4+ T cells, CD8+ T cells and macrophages/microglia in the spinal cord were reduced to different extents.The results collectively provide evidence that TSIIA alleviates EAE and support its utility as a novel therapy for MS.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology, The Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China.

ABSTRACT
Multiple sclerosis (MS) is an inflammatory autoimmune neurodegenerative disease, which features focal demyelination and inflammatory cell infiltration of the brain and the spinal cord. Tanshinone IIA (TSIIA), one of the major fat‑soluble components of Salvia miltiorrhiza (Danshen), has anti‑inflammatory, immunoregulatory and neuroprotective activity; however, its efficacy in MS remains unknown. The current study was designed to investigate the potential therapeutic function of TSIIA on MS in the experimental autoimmune encephalomyelitis (EAE) rat model. In comparison to the vehicle control group, the TSIIA‑treated groups showed notably improved clinical symptoms and pathological changes, including central nervous system inflammatory cell infiltration and demyelination. Following administration of TSIIA, the quantity of CD4+ T cells, CD8+ T cells and macrophages/microglia in the spinal cord were reduced to different extents. Furthermore, TSIIA was also shown to downregulate interleukin (IL)‑17 and IL‑23 levels in the brain and serum of EAE rats. The results collectively provide evidence that TSIIA alleviates EAE and support its utility as a novel therapy for MS.

No MeSH data available.


Related in: MedlinePlus

(A) Determination of CD4, CD8, Mac-1, IL-17 and IL-23 protein expression via western blot analysis. Quantitative analysis of (B) CD4, (C) CD8, (D) Mac-1, (E) IL-17 and (F) IL-23. Values are presented as the mean ± standard deviation (n=10 per group). ΔP<0.01, compared with the naive group; *P<0.01, compared with the vehicle group; #P<0.01, ##P<0.05 or n (not significant) compared with the TSIIA-H group. TSIIA, Tanshinone IIA; IL, interleukin; TSIIA-L, TSIIA low dose; TSIIA-H, TSIIA high dose.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4940100&req=5

f4-mmr-14-02-1601: (A) Determination of CD4, CD8, Mac-1, IL-17 and IL-23 protein expression via western blot analysis. Quantitative analysis of (B) CD4, (C) CD8, (D) Mac-1, (E) IL-17 and (F) IL-23. Values are presented as the mean ± standard deviation (n=10 per group). ΔP<0.01, compared with the naive group; *P<0.01, compared with the vehicle group; #P<0.01, ##P<0.05 or n (not significant) compared with the TSIIA-H group. TSIIA, Tanshinone IIA; IL, interleukin; TSIIA-L, TSIIA low dose; TSIIA-H, TSIIA high dose.

Mentions: To identify the types of infiltrating cells in the CNS of EAE rats, immunohistochemistry was performed. Inflammatory exudates included a mixture of cell types, including CD4+ T cells, CD8+ T cells, microglia and macrophages (Fig. 3A–L). Compared with the vehicle group, TSIIA administration at the two doses induced a significant decrease in the quantity of CD4+ T cells (P<0.01), CD8+ T cells (P<0.01), macrophages and microglia (P<0.01) (Fig. 3M–O). The results were confirmed by quantification of the western blots and were consistent with the results of immunostaining (P<0.05; Fig. 4A, B and C).


Tanshinone IIA attenuates experimental autoimmune encephalomyelitis in rats.

Yan J, Yang X, Han D, Feng J - Mol Med Rep (2016)

(A) Determination of CD4, CD8, Mac-1, IL-17 and IL-23 protein expression via western blot analysis. Quantitative analysis of (B) CD4, (C) CD8, (D) Mac-1, (E) IL-17 and (F) IL-23. Values are presented as the mean ± standard deviation (n=10 per group). ΔP<0.01, compared with the naive group; *P<0.01, compared with the vehicle group; #P<0.01, ##P<0.05 or n (not significant) compared with the TSIIA-H group. TSIIA, Tanshinone IIA; IL, interleukin; TSIIA-L, TSIIA low dose; TSIIA-H, TSIIA high dose.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4940100&req=5

f4-mmr-14-02-1601: (A) Determination of CD4, CD8, Mac-1, IL-17 and IL-23 protein expression via western blot analysis. Quantitative analysis of (B) CD4, (C) CD8, (D) Mac-1, (E) IL-17 and (F) IL-23. Values are presented as the mean ± standard deviation (n=10 per group). ΔP<0.01, compared with the naive group; *P<0.01, compared with the vehicle group; #P<0.01, ##P<0.05 or n (not significant) compared with the TSIIA-H group. TSIIA, Tanshinone IIA; IL, interleukin; TSIIA-L, TSIIA low dose; TSIIA-H, TSIIA high dose.
Mentions: To identify the types of infiltrating cells in the CNS of EAE rats, immunohistochemistry was performed. Inflammatory exudates included a mixture of cell types, including CD4+ T cells, CD8+ T cells, microglia and macrophages (Fig. 3A–L). Compared with the vehicle group, TSIIA administration at the two doses induced a significant decrease in the quantity of CD4+ T cells (P<0.01), CD8+ T cells (P<0.01), macrophages and microglia (P<0.01) (Fig. 3M–O). The results were confirmed by quantification of the western blots and were consistent with the results of immunostaining (P<0.05; Fig. 4A, B and C).

Bottom Line: Tanshinone IIA (TSIIA), one of the major fat‑soluble components of Salvia miltiorrhiza (Danshen), has anti‑inflammatory, immunoregulatory and neuroprotective activity; however, its efficacy in MS remains unknown.Following administration of TSIIA, the quantity of CD4+ T cells, CD8+ T cells and macrophages/microglia in the spinal cord were reduced to different extents.The results collectively provide evidence that TSIIA alleviates EAE and support its utility as a novel therapy for MS.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology, The Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China.

ABSTRACT
Multiple sclerosis (MS) is an inflammatory autoimmune neurodegenerative disease, which features focal demyelination and inflammatory cell infiltration of the brain and the spinal cord. Tanshinone IIA (TSIIA), one of the major fat‑soluble components of Salvia miltiorrhiza (Danshen), has anti‑inflammatory, immunoregulatory and neuroprotective activity; however, its efficacy in MS remains unknown. The current study was designed to investigate the potential therapeutic function of TSIIA on MS in the experimental autoimmune encephalomyelitis (EAE) rat model. In comparison to the vehicle control group, the TSIIA‑treated groups showed notably improved clinical symptoms and pathological changes, including central nervous system inflammatory cell infiltration and demyelination. Following administration of TSIIA, the quantity of CD4+ T cells, CD8+ T cells and macrophages/microglia in the spinal cord were reduced to different extents. Furthermore, TSIIA was also shown to downregulate interleukin (IL)‑17 and IL‑23 levels in the brain and serum of EAE rats. The results collectively provide evidence that TSIIA alleviates EAE and support its utility as a novel therapy for MS.

No MeSH data available.


Related in: MedlinePlus